Literature DB >> 1672255

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.

S M O'Reilly1, D M Barnes, R S Camplejohn, J Bartkova, W M Gregory, M A Richards.   

Abstract

The relationship between c-erbB-2 gene expression (assessed immunohistochemically), S-phase fraction (SPF) and prognosis has been analysed in 172 women with primary breast cancer. c-erbB-2 staining was independent of age, tumour size, number of nodes involved, tumour grade and DNA ploidy, but was more common in oestrogen receptor (ER) negative tumours (P = 0.02) and progesterone receptor (PgR) negative tumours (P = 0.03). A weak correlation between c-erbB-2 staining and SPF was observed (r = 0.18). Amongst women with node negative disease, SPF was significantly related to relapse free survival (RFS, P = 0.04) while c-erbB-2 staining was not (P = 0.2). In contrast, both SPF (P = 0.002) and c-erbB-2 staining (P = 0.016) provided significant prognostic information on RFS for women with node positive disease. Multivariate analysis showed that c-erbB-2 staining and SPF gave independent information on RFS for women with node positive disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672255      PMCID: PMC1971877          DOI: 10.1038/bjc.1991.102

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle.

Authors:  H Baisch; W Göhde; W A Linden
Journal:  Radiat Environ Biophys       Date:  1975-06-13       Impact factor: 1.925

2.  Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.

Authors:  S M O'Reilly; R S Camplejohn; D M Barnes; R R Millis; R D Rubens; M A Richards
Journal:  J Clin Oncol       Date:  1990-12       Impact factor: 44.544

3.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

4.  Expression of the c-erbB-2 protein in normal and transformed cells.

Authors:  W J Gullick; M S Berger; P L Bennett; J B Rothbard; M D Waterfield
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

5.  Amplification of c-erbB-2 and aggressive human breast tumors?

Authors:  D J Slamon; G M Clark
Journal:  Science       Date:  1988-06-24       Impact factor: 47.728

6.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

7.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

Authors:  C Wright; B Angus; S Nicholson; J R Sainsbury; J Cairns; W J Gullick; P Kelly; A L Harris; C H Horne
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

8.  HER-2/neu oncogene protein and prognosis in breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; A Ullrich; W L McGuire
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

9.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.

Authors:  D M Barnes; G A Lammie; R R Millis; W L Gullick; D S Allen; D G Altman
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  DNA index, S-phase fraction, histological grade and prognosis in breast cancer.

Authors:  S M O'Reilly; R S Camplejohn; D M Barnes; R R Millis; D Allen; R D Rubens; M A Richards
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

View more
  26 in total

1.  Flow Cytometric Assay of c-erbB-2 Protein in Fine Needle Aspirates of Fresh and Frozen Human Breast Cancer Tissues.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

2.  Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.

Authors:  R J Epstein; B J Druker; T M Roberts; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

3.  Human mammary epithelial cells in primary culture reflect c-myc and c-erbB-2 gene copy number in tissue.

Authors:  J T Emerman; S L Wilson; D A Wilkinson; D M Moore; P M Rebbeck
Journal:  In Vitro Cell Dev Biol       Date:  1992-06

4.  Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.

Authors:  D M Barnes; J S Meyer; J G Gonzalez; W J Gullick; R R Millis
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

5.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

6.  Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast Cancer.

Authors:  V Dutta; G S Chopra; K Sahai; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

8.  The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer.

Authors:  Mohammad W Khan; Abdulrahman Saadalla; Ahmed H Ewida; Khalid Al-Katranji; Ghadier Al-Saoudi; Zachary T Giaccone; Fotini Gounari; Ming Zhang; David A Frank; Khashayarsha Khazaie
Journal:  Cancer Immunol Immunother       Date:  2017-09-05       Impact factor: 6.968

Review 9.  Endocrine therapy for advanced breast cancer: a review.

Authors:  H B Muss
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 10.  Natural history of human breast cancer: recent data and clinical implications.

Authors:  M Tubiana; S Koscielny
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.